The Ledger

Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.

clear all ✕

why aren't all 51 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable

Assertion Supported
Ricks: Tirzepatide's US patent extends into the late 2030s
“I think Terseptide's U.S. Patent is late thirties or foregrip on the oral beyond that.”
Dave Ricks Nov 11, 2025 ▶ 1:49:39 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Assertion Supported
Ricks: Lilly R&D spend is growing ~20% while headcount grows single digits
“So we're growing R&D high teens, early low twenties. We're growing headcount in R&D single digits.”
Dave Ricks Nov 11, 2025 ▶ 2:04:28 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Assertion Supported
Ricks: Lilly has had 11 CEOs in 150 years, only one external
“We've had a 150 years of that, and I'm the 11th CEO of the company. That's one less than Pope's in that period of time. So that's, it was a special honor, actually, and it's not a lifetime appointment. I can be fired any day, but the first four were family mem…”
Dave Ricks Nov 11, 2025 ▶ 2:03:02 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Made with StarZero

Turn any episode into a week of clips.

This entire site, about 28 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.